Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Biohaven Ltd. (BHVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.21 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 493.35K shares, a 59.14% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 4.72M shares, a 73.13% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 169.05K shares, a 5534.93% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.21M shares, a 27.90% increase from fiscal 2024.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.51M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 493.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 5.21M shares 10-Q · filed 2026-08-10 | 5.21M shares derived: sum of 3 quarters · filed 2026-08-10 | 5.38M shares derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | 4.72M shares 10-Q · filed 2026-05-04 | 4.72M shares derived: sum of 2 quarters · filed 2026-05-04 | 4.89M shares derived: sum of 3 quarters · filed 2026-05-04 | 5.20M shares derived: sum of 4 quarters · filed 2026-05-04 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 169.05K shares derived: sum of 2 quarters · filed 2026-03-02 | 479.06K shares derived: sum of 3 quarters · filed 2026-03-02 | 3.21M shares 10-K · filed 2026-03-02 | |
| 2025-09-30 | 169.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 479.06K shares derived: sum of 2 quarters · filed 2025-11-10 | 3.21M shares 10-Q · filed 2025-11-10 | 3.21M shares derived: sum of 4 quarters · filed 2025-11-10 | |
| 2025-06-30 | 310.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 3.04M shares 10-Q · filed 2025-08-11 | 3.04M shares derived: sum of 3 quarters · filed 2025-08-11 | 3.04M shares derived: sum of 4 quarters · filed 2025-08-11 | |
| 2025-03-31 | 2.73M shares 10-Q · filed 2025-05-12 | 2.73M shares derived: sum of 2 quarters · filed 2025-05-12 | 2.73M shares derived: sum of 3 quarters · filed 2025-05-12 | 2.85M shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 3.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 6.00K shares derived: sum of 2 quarters · filed 2025-03-03 | 126.14K shares derived: sum of 3 quarters · filed 2025-03-03 | 2.51M shares 10-K · filed 2025-03-03 | |
| 2024-09-30 | 3.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 123.14K shares derived: sum of 2 quarters · filed 2024-11-12 | 2.50M shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 120.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 2.50M shares 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 2.38M shares 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 2.93M shares 10-K · filed 2024-02-29 | 13.17M shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |